Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

The research team, led by Darrell Kotton, MD, and Anthony Hollenberg, MD, has developed a successful protocol for producing ...

Follicular lymphoma is a diverse disease ... Finally, hematopoietic stem cell transplantation (both autologous and allogeneic) remains a useful treatment strategy, although the optimal timing ...

Faia and colleagues reported that duvelisib exhibited growth inhibitory activity in a variety of malignant hematologic cell lines, including DOHH-2 and WSU-NHL, both of which represent transformed FL.

One of the most common forms of Non-Hodgkin's lymphoma is follicular lymphoma, a slow growing blood cancer that affects your immune system. It occurs when infection fighting white cells called B ...

Incyte’s previously disclosed phase 3 win in relapsed or refract | In the phase 3 inMIND study, Monjuvi—added to Bristol ...

What’s the next step for this patient with a 4-year history of low-grade follicular lymphoma and who now has worsening lymphadenopathy and needs a nap at the end of every work day? Share on ...

Monjuvi, Revlimid and Rituxan improved progression-free survival among adults with relapsed or refractory follicular lymphoma, topline research showed.

Late-breaking data presentation at ASH will feature results from the Phase 3 inMIND study evaluating tafasitamab in ...

The global CAR-T Cell Therapy market size is expected to reach USD 8.92 billion by 2026 growing at a CAGR of 34.5% from 2020 to 2026 according to a new study published by Report Ocean. Request To ...